| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1146/ANNUREV.BIOCHEM.74.082803.133400 |
| P698 | PubMed publication ID | 15952880 |
| P50 | author | Mark R Cookson | Q67168137 |
| P2860 | cites work | Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism | Q24309753 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P1104 | number of pages | 24 | |
| P304 | page(s) | 29-52 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Annual Review of Biochemistry | Q567356 |
| P1476 | title | The biochemistry of Parkinson's disease | |
| P478 | volume | 74 |
| Q47071664 | A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. |
| Q89736097 | A Role of Cholesterol in Modulating the Binding of α-Synuclein to Synaptic-Like Vesicles |
| Q61799948 | A first order phase transition mechanism underlies protein aggregation in mammalian cells |
| Q41069719 | A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies. |
| Q40379153 | Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. |
| Q38020753 | Affinity and enzyme-based biosensors: recent advances and emerging applications in cell analysis and point-of-care testing |
| Q36428039 | Ageing and neuronal vulnerability |
| Q42322220 | Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome |
| Q52678048 | Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. |
| Q37401007 | Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells |
| Q28265926 | Aggresome formation and neurodegenerative diseases: therapeutic implications |
| Q42672352 | Alpha synuclein is transported into and out of the brain by the blood-brain barrier |
| Q42455430 | Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease |
| Q24301946 | Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity |
| Q50300614 | Alpha-synuclein alters differently gene expression of Sirts, PARPs and other stress response proteins: implications for neurodegenerative disorders. |
| Q39575705 | Alpha-synuclein binds large unilamellar vesicles as an extended helix |
| Q51807832 | Alteration in biochemical parameters in the brain of transgenic Drosophila melanogaster model of Parkinson's disease exposed to apigenin. |
| Q36907399 | Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice |
| Q57168813 | An updated analysis with 45,078 subjects confirms the association between SNCA rs11931074 and Parkinson's disease |
| Q37824973 | Analyzing the aggregation of polyglutamine-expansion proteins and its modulation by molecular chaperones |
| Q38088284 | Animal models for drug discovery in dystonia |
| Q92571880 | Antibiotic Minocycline Prevents Respiratory Syncytial Virus Infection |
| Q34130806 | Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation |
| Q64865563 | Asiatic Acid Prevents Oxidative Stress and Apoptosis by Inhibiting the Translocation of α-Synuclein Into Mitochondria |
| Q24282619 | Association between Parkinson's Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis |
| Q24319830 | Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease |
| Q38200488 | Association of glycogen synthase kinase-3β with Parkinson's disease (review). |
| Q36907208 | Autophagic failure promotes the exocytosis and intercellular transfer of α-synuclein. |
| Q37614744 | Axonal transport defects in neurodegenerative diseases |
| Q37590635 | Back to the tubule: microtubule dynamics in Parkinson's disease |
| Q44582977 | Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation |
| Q35908559 | Basal ganglia dopamine loss due to defect in purine recycling |
| Q46925606 | Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles |
| Q34769745 | Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background |
| Q36755348 | Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics |
| Q50479107 | Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration. |
| Q48550878 | Brain injection of α-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. |
| Q28475159 | Brugia malayi excreted/secreted proteins at the host/parasite interface: stage- and gender-specific proteomic profiling |
| Q50990181 | CDK5-Mediated Phosphorylation-Dependent Ubiquitination and Degradation of E3 Ubiquitin Ligases GP78 Accelerates Neuronal Death in Parkinson's Disease. |
| Q26799640 | CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases |
| Q35757239 | Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation |
| Q42739339 | Caspase-cleaved transactivation response DNA-binding protein 43 in Parkinson's disease and dementia with Lewy bodies |
| Q36440972 | Cell systems and the toxic mechanism(s) of alpha-synuclein |
| Q36528609 | Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines |
| Q38194531 | Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease. |
| Q43256880 | Characterization of intrinsically disordered proteins with electrospray ionization mass spectrometry: conformational heterogeneity of alpha-synuclein |
| Q44738578 | Characterization of three synuclein genes in Xenopus laevis. |
| Q61816513 | Chip Based Electroanalytical Systems for Cell Analysis |
| Q30450371 | Chronic overload of SEPT4, a parkin substrate that aggregates in Parkinson's disease, causes behavioral alterations but not neurodegeneration in mice |
| Q34052764 | Clinical progression in Parkinson disease and the neurobiology of axons. |
| Q37346316 | Comparison of the brain penetration injury associated with microdialysis and voltammetry |
| Q47647268 | Comparison of the in vivo induction and transmission of α-synuclein pathology by mutant α-synuclein fibril seeds in transgenic mice |
| Q48058974 | Computational investigation on the effects of H50Q and G51D mutations on the α-Synuclein aggregation propensity |
| Q83275101 | Conformational isomers of denatured and unfolded proteins: methods of production and applications |
| Q41494001 | Conformational templating of α-synuclein aggregates in neuronal-glial cultures |
| Q36400476 | Consequences of impaired purine recycling in dopaminergic neurons |
| Q37148963 | Copper(II) binding to alpha-synuclein, the Parkinson's protein |
| Q47659411 | Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model |
| Q39178579 | Curcumin modulates α-synuclein aggregation and toxicity. |
| Q33755817 | DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity |
| Q34185176 | Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins |
| Q37479332 | Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization |
| Q44143951 | Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. |
| Q35175448 | Direct observation of the three regions in α-synuclein that determine its membrane-bound behaviour |
| Q33726660 | Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies |
| Q91429961 | Dissecting α-synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis |
| Q37076753 | Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum |
| Q28392011 | Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance |
| Q33948478 | Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation |
| Q48426203 | Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. |
| Q39255917 | E3 ubiquitin ligase NKLAM is a macrophage phagosome protein and plays a role in bacterial killing. |
| Q45900041 | E3 ubiquitin ligase NKLAM ubiquitinates STAT1 and positively regulates STAT1-mediated transcriptional activity. |
| Q35266392 | E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment |
| Q57269969 | EGFR trafficking: parkin' in a jam |
| Q34468291 | ER stress response plays an important role in aggregation of α-synuclein |
| Q48447184 | Effect of L-ascorbic Acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson's disease. |
| Q64055243 | Effect of Majun Baladur on life span, climbing ability, oxidative stress and dopaminergic neurons in the transgenic model of Parkinson's disease |
| Q38734429 | Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes. |
| Q39659132 | Effect of curcumin analogs onα-synuclein aggregation and cytotoxicity. |
| Q83740013 | Effect of the A30P mutation on the structural dynamics of micelle-bound αSynuclein released in water: a molecular dynamics study |
| Q28834531 | Effects of Mutations on the Reconfiguration Rate of α-Synuclein |
| Q33527392 | Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease |
| Q36325667 | Evolution of neurodegeneration |
| Q36404133 | Expanding insights of mitochondrial dysfunction in Parkinson's disease. |
| Q36569704 | Experimental therapeutics for dystonia |
| Q39292701 | Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. |
| Q37855889 | Finding order within disorder: elucidating the structure of proteins associated with neurodegenerative disease |
| Q40105806 | Formaldehyde at low concentration induces protein tau into globular amyloid-like aggregates in vitro and in vivo. |
| Q28472448 | Formation of toxic oligomeric alpha-synuclein species in living cells |
| Q46783900 | Fully automated microchip system for the detection of quantal exocytosis from single and small ensembles of cells |
| Q35001040 | GSK-3 in Neurodegenerative Diseases. |
| Q33389138 | Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology |
| Q37951515 | Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit. |
| Q50710454 | Genetic analysis of α-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies. |
| Q37765030 | Genetic animal models of Parkinson's disease |
| Q22252904 | Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update |
| Q34825312 | Genetic neuropathology of Parkinson's disease. |
| Q80679633 | Genetics of parkinsonism |
| Q41448283 | Global stress response in a prokaryotic model of DJ-1-associated Parkinsonism. |
| Q33563387 | Glycoproteomics in neurodegenerative diseases |
| Q28116395 | Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase |
| Q57092849 | High density lipoproteins bind Aβ and apolipoprotein C-II amyloid fibrils |
| Q28392567 | How Parkinsonian toxins dysregulate the autophagy machinery |
| Q41314313 | Hydrogen exchange of monomeric alpha-synuclein shows unfolded structure persists at physiological temperature and is independent of molecular crowding in Escherichia coli |
| Q37079316 | Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. |
| Q37401579 | Identification of the minimal copper(II)-binding alpha-synuclein sequence. |
| Q40084956 | Identifying altered gene expression in neuroblastoma cells preceding apoptosis |
| Q36058297 | Impact of N-terminal acetylation of α-synuclein on its random coil and lipid binding properties |
| Q42556314 | Impact of microdialysis probes on vasculature and dopamine in the rat striatum: a combined fluorescence and voltammetric study |
| Q38631574 | Impaired endo-lysosomal membrane integrity accelerates the seeding progression of α-synuclein aggregates |
| Q93389094 | In-Cell NMR Spectroscopy of Intrinsically Disordered Proteins |
| Q28535612 | In-cell NMR characterization of the secondary structure populations of a disordered conformation of α-synuclein within E. coli cells |
| Q24655848 | Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein |
| Q37083992 | Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains |
| Q37484884 | Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein |
| Q36902253 | Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders |
| Q36776350 | Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease |
| Q41957629 | Integrity of N- and C-termini is important for E. coli Hsp31 chaperone activity |
| Q41871354 | Interaction map and selection of microRNA targets in Parkinson's disease-related genes |
| Q30577687 | Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease |
| Q30585365 | Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. |
| Q33735667 | Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity |
| Q42636162 | Investigate the chronic neurotoxic effects of diquat. |
| Q45118902 | Is trehalose an autophagic inducer? Unraveling the roles of non-reducing disaccharides on autophagic flux and alpha-synuclein aggregation |
| Q24338903 | JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress |
| Q36320550 | Keratin 8 overexpression promotes mouse Mallory body formation |
| Q36794416 | LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease |
| Q43152258 | Lardy brains make Parkinson's disease mice worse |
| Q48106683 | Let-7d microRNA Attenuates 6-OHDA-Induced Injury by Targeting Caspase-3 in MN9D Cells. |
| Q33812599 | Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease |
| Q37225356 | Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions |
| Q64866037 | Localized Induction of Wild-Type and Mutant Alpha-Synuclein Aggregation Reveals Propagation along Neuroanatomical Tracts |
| Q43518984 | Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain |
| Q36325784 | Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. |
| Q38488082 | Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role |
| Q37082050 | Mechanisms of neurodegeneration in idiopathic Parkinson's disease |
| Q48160855 | Melatonin as a mitochondrial protector in neurodegenerative diseases |
| Q37348374 | Membrane compartments and purinergic signalling: P2X receptors in neurodegenerative and neuroinflammatory events. |
| Q30155431 | Membrane proteins in four acts: function precedes structure determination. |
| Q36841249 | Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults |
| Q30009951 | Microcanonical thermostatistics of coarse-grained proteins with amyloidogenic propensity. |
| Q39986517 | Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease |
| Q34170717 | Mitochondria and neuroplasticity |
| Q35412397 | Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? |
| Q33459240 | Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. |
| Q36727241 | Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain |
| Q37556779 | Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases |
| Q37853789 | Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease |
| Q43157334 | Molecular determinants of the aggregation behavior of alpha- and beta-synuclein |
| Q28298685 | Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells |
| Q37749063 | Molecular mechanisms of pathogenesis of Parkinson's disease. |
| Q37021321 | Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside |
| Q34115959 | Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. |
| Q35734379 | NMR Metabolomics Analysis of Parkinson's Disease |
| Q42649841 | NMR determination of pKa values in α-synuclein |
| Q36179280 | Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia |
| Q37968055 | Neurodegeneration and inflammation in Parkinson's disease |
| Q34079770 | Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis |
| Q46790757 | Neurons inflict self-harm |
| Q34648491 | Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation |
| Q33821316 | Neuroproteomics as a promising tool in Parkinson's disease research |
| Q39486562 | Neurotrophic effects of growth/differentiation factor 5 in a neuronal cell line. |
| Q94594710 | Nitroxide Radical-Containing Redox Nanoparticles Protect Neuroblastoma SH-SY5Y Cells against 6-Hydroxydopamine Toxicity |
| Q64061136 | Novel Mannitol-Based Small Molecules for Inhibiting Aggregation of α-Synuclein Amyloids in Parkinson's Disease |
| Q24306217 | Nutrient deprivation induces α-synuclein aggregation through endoplasmic reticulum stress response and SREBP2 pathway |
| Q40132686 | On the oligomeric state of DJ-1 protein and its mutants associated with Parkinson Disease. A combined computational and in vitro study. |
| Q36709104 | On-surface aggregation of α-synuclein at nanomolar concentrations results in two distinct growth mechanisms |
| Q37375495 | Onjisaponin B derived from Radix Polygalae enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin in PC-12 cells |
| Q36710261 | Oxidative and nitrative protein modifications in Parkinson's disease |
| Q82029447 | Oxidative stress and Parkinson's disease |
| Q35266403 | Oxidized DJ-1 interacts with the mitochondrial protein BCL-XL. |
| Q36871156 | P268S in NOD2 associates with susceptibility to Parkinson's disease in Chinese population |
| Q34084176 | PINK1 triggers autocatalytic activation of Parkin to specify cell fate decisions |
| Q57243906 | PINK1: one protein, multiple neuroprotective functions |
| Q38289431 | Parkin expression profile in dopamine d3 receptor knock-out mice brains. |
| Q28296466 | Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of c-Jun NH2-terminal kinase |
| Q24312713 | Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation |
| Q24679424 | Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels |
| Q39714333 | Parkinson disease-associated DJ-1 is required for the expression of the glial cell line-derived neurotrophic factor receptor RET in human neuroblastoma cells. |
| Q24305472 | Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model |
| Q24306921 | Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs methylglyoxal- and glyoxal-glycated cysteine, arginine, and lysine residues |
| Q33574527 | Phagocytosis of microglia in the central nervous system diseases |
| Q39582058 | Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease |
| Q40165778 | Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. |
| Q37303879 | Potential role of alpha-synuclein and metallothionein in lead-induced inclusion body formation |
| Q36444517 | Premotor biomarkers for Parkinson's disease - a promising direction of research |
| Q34091754 | Preventing Ca2+-mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies |
| Q48090188 | Prion-like transmission of α-synuclein pathology in the context of an NFL null background |
| Q28473591 | Pro-survival role for Parkinson's associated gene DJ-1 revealed in trophically impaired dopaminergic neurons |
| Q37014379 | Proaggregant nuclear factor(s) trigger rapid formation of α-synuclein aggregates in apoptotic neurons |
| Q34859364 | Programmed cell death and new discoveries in the genetics of parkinsonism. |
| Q27322513 | Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies |
| Q34423923 | Protective Role of rAAV-NDI1, Serotype 5, in an Acute MPTP Mouse Parkinson's Model |
| Q48201813 | Protective effects of curcumin against rotenone-induced rat model of Parkinson's disease: in vivo electrophysiological and behavioral study |
| Q33795993 | Protein aggregation in a mutant deficient in yajL, the bacterial homolog of the Parkinsonism-associated protein DJ-1 |
| Q36501365 | Protein misfolding disorders: pathogenesis and intervention |
| Q36127050 | Proteolytic cleavage of extracellular α-synuclein by plasmin: implications for Parkinson disease |
| Q38761409 | Proteomic studies associated with Parkinson's disease. |
| Q37800101 | Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies |
| Q24313263 | RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways |
| Q36305419 | RNA knockdown as a potential therapeutic strategy in Parkinson's disease. |
| Q42757707 | ROS removal by DJ-1: Arabidopsis as a new model to understand Parkinson's Disease |
| Q39817121 | Reciprocal effects of alpha-synuclein overexpression and proteasome inhibition in neuronal cells and tissue |
| Q24299645 | Redistribution of DAT/α-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease |
| Q37718085 | Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases |
| Q37697045 | Redox regulation of mitochondrial fission, protein misfolding, synaptic damage, and neuronal cell death: potential implications for Alzheimer's and Parkinson's diseases |
| Q38024581 | Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases |
| Q39349479 | Regulation of Escherichia coli hchA, a stress-inducible gene encoding molecular chaperone Hsp31. |
| Q24293089 | Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity |
| Q64868285 | Remote control of movement disorders using a photoactive adenosine A2A receptor antagonist |
| Q34779845 | Residue-specific fluorescent probes of α-synuclein: detection of early events at the N- and C-termini during fibril assembly |
| Q37560714 | Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of α-Synuclein Fibrils |
| Q34192817 | Role of LRRK2 kinase dysfunction in Parkinson disease |
| Q27021384 | Role of protein kinase A in regulating mitochondrial function and neuronal development: implications to neurodegenerative diseases |
| Q47260625 | Running wheel exercise reduces α-synuclein aggregation and improves motor and cognitive function in a transgenic mouse model of Parkinson's disease. |
| Q37784820 | S-nitrosylation of critical protein thiols mediates protein misfolding and mitochondrial dysfunction in neurodegenerative diseases |
| Q28286470 | Selective degeneration of dopaminergic neurons by MPP(+) and its rescue by D2 autoreceptors in Drosophila primary culture |
| Q37003019 | Selective enrichment of DJ-1 protein in primate striatal neuronal processes: implications for Parkinson's disease |
| Q34250768 | Single molecule characterization of α-synuclein in aggregation-prone states |
| Q41870217 | Single-molecule fluorescence spectroscopy using phospholipid bilayer nanodiscs |
| Q28817941 | Solid-state ¹³C NMR reveals annealing of raft-like membranes containing cholesterol by the intrinsically disordered protein α-Synuclein |
| Q38728113 | Specificity and disease in the ubiquitin system |
| Q47361450 | Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term |
| Q52675832 | Stimulation of α-synuclein amyloid formation by phosphatidylglycerol micellar tubules. |
| Q41911876 | Structural Ensembles of Membrane-bound α-Synuclein Reveal the Molecular Determinants of Synaptic Vesicle Affinity |
| Q37273635 | Structural basis of synaptic vesicle assembly promoted by α-synuclein |
| Q35903351 | Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice |
| Q35682515 | Studies of protein aggregation in A53T α-synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice. |
| Q40002714 | Sumoylation is critical for DJ-1 to repress p53 transcriptional activity. |
| Q37972089 | Synaptic protein alterations in Parkinson's disease. |
| Q41979984 | Syndromic approach to Parkinson's disease: role of functional imaging |
| Q50554031 | Synphilin-1 inhibits alpha-synuclein degradation by the proteasome. |
| Q58586744 | Tau Pathology in Parkinson's Disease |
| Q48686425 | Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. |
| Q35059247 | Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake |
| Q35764789 | The A53E α-synuclein pathological mutation demonstrates reduced aggregation propensity in vitro and in cell culture |
| Q38677249 | The Antisense Transcriptome and the Human Brain. |
| Q37440893 | The E163K DJ-1 mutant shows specific antioxidant deficiency |
| Q90672285 | The Effect of Neurotoxin MPTP and Neuroprotector Isatin on the Profile of Ubiquitinated Brain Mitochondrial Proteins |
| Q91920062 | The Molecular Basis of the Interaction of Cyclophilin A with α-Synuclein |
| Q39196741 | The Parkinson's disease-associated GPR37 receptor-mediated cytotoxicity is controlled by its intracellular cysteine-rich domain. |
| Q36154267 | The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity |
| Q51621418 | The RNA dreamtime: modern cells feature proteins that might have supported a prebiotic polypeptide world but nothing indicates that RNA world ever was. |
| Q30273796 | The effects of oxidative stress on parkin and other E3 ligases |
| Q36812817 | The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. |
| Q36735295 | The fold of alpha-synuclein fibrils |
| Q36577255 | The genetics of Parkinson disease: Implications for neurological care |
| Q43095684 | The homocysteine-inducible endoplasmic reticulum stress protein counteracts calcium store depletion and induction of CCAAT enhancer-binding protein homologous protein in a neurotoxin model of Parkinson disease. |
| Q33278821 | The human PINK1 locus is regulated in vivo by a non-coding natural antisense RNA during modulation of mitochondrial function |
| Q33696177 | The interaction of alphaB-crystallin with mature alpha-synuclein amyloid fibrils inhibits their elongation |
| Q35612163 | The loss of glucose-regulated protein 78 (GRP78) during normal aging or from siRNA knockdown augments human alpha-synuclein (α-syn) toxicity to rat nigral neurons |
| Q36393039 | The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease |
| Q38582520 | The possible involvement of mitochondrial dysfunctions in Lewy body dementia: a systematic review. |
| Q36762636 | The ring between ring fingers (RBR) protein family |
| Q30386079 | The sour side of neurodegenerative disorders: the effects of protein glycation. |
| Q28830423 | Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein |
| Q41605202 | Toxin-induced and genetic animal models of Parkinson's disease |
| Q38426673 | Transgenic zebrafish expressing green fluorescent protein in dopaminergic neurons of the ventral diencephalon |
| Q34309349 | Translational defects in a mutant deficient in YajL, the bacterial homolog of the parkinsonism-associated protein DJ-1. |
| Q36384570 | Ubiquitin ligases, critical mediators of endoplasmic reticulum-associated degradation |
| Q37775037 | Understanding the molecular basis of Parkinson's disease, identification of biomarkers and routes to therapy |
| Q34201811 | Unravelling the role of defective genes |
| Q84792017 | Variant in the 3' region of SNCA associated with Parkinson's disease and serum α-synuclein levels |
| Q41481673 | YajL, prokaryotic homolog of parkinsonism-associated protein DJ-1, functions as a covalent chaperone for thiol proteome. |
| Q50499008 | Zebrafish Parla- and Parlb-deficiency affects dopaminergic neuron patterning and embryonic survival. |
| Q21202835 | alpha-Synuclein and neuronal cell death |
| Q36663027 | alpha-synuclein and Parkinson's disease: the first roadblock |
| Q45899836 | α - synuclein and Parkinson’s disease: the first roadblock. |
| Q48392245 | α-Synuclein forms non-selective cation channels and stimulates ATP-sensitive potassium channels in hippocampal neurons. |
| Q36685114 | α-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. |
| Q39574142 | α-Synuclein overexpression enhances manganese-induced neurotoxicity through the NF-κB-mediated pathway |
| Q30500318 | α-Synuclein-induced tubule formation in lipid bilayers |
| Q42374822 | β-Synuclein suppresses both the initiation and amplification steps of α-synuclein aggregation via competitive binding to surfaces. |
Search more.